Compare Abeona Therapeutics Inc (ABEO) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco DB Oil Fund — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while Invesco DB Oil Fund trades at $21.06. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | DBO | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Commodities - Energy |
52-Week High | $7.45 | $23.80 |
52-Week Low | $4.17 | $11.98 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
DBO trades at $19.59, down 0.41% on the day, with a bearish technical signal from moving averages and oscillators showing neutrality. The stock faces resistance at $20 and support at $19. Recent news highlights oil price volatility due to Middle East tensions, particularly the Strait of Hormuz deadlock, which may impact energy sector stocks like DBO.
The outlook for DBO is cautious amid geopolitical risks and technical bearishness. Investment opportunities hinge on resolution of oil supply constraints, while risks include prolonged Middle East instability and potential earnings pressure from fluctuating crude prices. Wall Street sentiment appears mixed, with no clear consensus on near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
